Allovir Inc (KLRS) Stock Forecast & Price Target

Kalaris Therapeutics is attractive because TH103 is engineered to address the biggest unmet need in wet AMD: durable VEGF suppression with less frequent intravitreal dosing, supported by high-affinity VEGFR1 binding and HSPG-mediated retinal retention. Early Phase Ia data strengthen that thesis, with a single dose producing about a 10-letter BCVA gain, ~129 µm CST reduction, ~95% intraretinal fluid reduction, and 31% of patients requiring no retreatment through six months, while manufacturing refinements appear to have reduced inflammation risk. The commercial opportunity is large, with wet AMD in a $15B+ market and a conservative peak sales estimate of $1.6B by 2040, leaving meaningful upside if repeat dosing further validates efficacy and durability.

Kalaris Therapeutics is a single-asset, clinical-stage biotech with no approved products, so its valuation hinges almost entirely on TH103 succeeding in Phase 1b/2 and eventually clearing FDA and EMA hurdles, despite acknowledged clinical, manufacturing, and regulatory risks. The company ended 1Q26 with $104.9M of cash and management expects runway into 4Q27, but continued development and any commercialization effort will likely require additional capital that could be dilutive. Even if approved, TH103 would enter a crowded wet AMD market dominated by entrenched therapies like Eylea and Vabysmo, where real-world use is constrained by 5–8 injections per year, payer pressure, and weak economics for biosimilars, making market penetration uncertain.